Research graph
References from Innovative Therapeutics. Local targets link to admitted publications; unresolved targets remain external evidence.
Recent trends in cardiovascular mortality in the United States and public health goals
10.1001/jamacardio.2016.1326 · 2016 · External reference
Angiotensin-neprilysin inhibition versus enalapril in heart failure
10.1056/nejmoa1409077 · 2014 · External reference
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics
10.1093/eurheartj/ehs262 · 2013 · External reference
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
10.1016/s0140-6736(09)61966-8 · 2010 · External reference
Protein engineering for cardiovascular therapeutics: untapped potential for cardiac repair
10.1161/circresaha.113.300215 · 2013 · External reference
Peptide therapeutics: current status and future directions
10.1016/j.drudis.2014.10.003 · 2015 · External reference
Liraglutide and cardiovascular outcomes in type 2 diabetes
10.1056/nejmoa1603827 · 2016 · External reference
Therapeutic applications of the cell-penetrating HIV-1 Tat peptide
10.1016/j.drudis.2014.09.017 · 2015 · External reference
Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial
10.1016/s0140-6736(12)61855-8 · 2013 · External reference
Natriuretic peptides
10.1056/nejm199807303390507 · 1998 · External reference
Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes
10.1172/jci59701 · 2012 · External reference
A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community
10.1016/j.jacc.2011.05.011 · 2011 · External reference
The natriuretic peptides and fat metabolism
10.1056/nejmcibr1204796 · 2012 · External reference
Biology of the natriuretic peptides
10.1016/j.amjcard.2007.11.012 · 2008 · External reference
The evolution of the natriuretic peptides - current applications in human and animal medicine
2009 · External reference
Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions
10.1210/er.2005-0014 · 2006 · External reference
A 'reverse' phylogenetic approach for identification of novel osmoregulatory and cardiovascular hormones in vertebrates
10.1016/j.yfrne.2007.05.001 · 2007 · External reference
Atrial natriuretic peptide clearance receptor. Complete sequence and functional expression of cDNA clones
10.1016/s0021-9258(19)76554-5 · 1988 · External reference
Natriuretic peptide receptor-C signaling and regulation
10.1016/j.peptides.2004.09.023 · 2005 · External reference
Differential activation of natriuretic peptide receptors modulates cardiomyocyte proliferation during development
10.1242/dev.100370 · 2014 · External reference
Endothelial C-type natriuretic peptide maintains vascular homeostasis
10.1172/jci74281 · 2014 · External reference
Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A
10.1161/01.res.0000094745.28948.4d · 2003 · External reference
Effects of synthetic atrial natriuretic factor on renal function and renin release
1984 · External reference
Chronic actions of a novel oral B-type natriuretic peptide conjugate in normal dogs and acute actions in angiotensin II-mediated hypertension
10.1161/circulationaha.107.759241 · 2008 · External reference
Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation
10.1161/circheartfailure.113.000885 · 2014 · External reference
Isolation and structural analysis of “urodilatin”, a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine
10.1007/bf01726570 · 1988 · External reference
Pro-atrial natriuretic peptide: a novel guanylyl cyclase-A receptor activator that goes beyond atrial and B-type natriuretic peptides
2015 · External reference
“BNP” for heart failure: role of nesiritide in cardiovascular therapeutics
10.1111/j.1527-5299.2002.01154.x · 2002 · External reference
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure
10.1161/circheartfailure.112.000289 · 2013 · External reference
Pro-B-type natriuretic peptide-1-108 processing and degradation in human heart failure
10.1161/circheartfailure.114.001174 · 2015 · External reference
Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure
10.1056/nejmoa020233 · 2002 · External reference
NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study
10.1093/eurheartj/ehi631 · 2006 · External reference
The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects
10.1016/j.jacc.2010.01.031 · 2010 · External reference
Cardiorenal fibrosis and dysfunction in aging: imbalance in mediators and regulators of collagen
10.1016/j.peptides.2016.01.004 · 2016 · External reference
A new member of the natriuretic peptide family is present in the venom of the green mamba (Dendroaspis angusticeps)
10.1016/s0021-9258(19)49658-0 · 1992 · External reference
Epidemiology of heart failure in a community-based study of subjects aged > or = 57 years: incidence and long-term survival
10.1016/j.ejheart.2005.04.012 · 2006 · External reference
Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP
10.1016/j.jacc.2012.05.049 · 2012 · External reference
M-atrial natriuretic peptide: a novel antihypertensive protein therapy
10.1007/s11906-011-0244-5 · 2012 · External reference
Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy
10.1016/s0002-9149(96)00464-x · 1996 · External reference
Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group
10.1056/nejm200007273430403 · 2000 · External reference
Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials
10.1001/jama.293.15.1900 · 2005 · External reference
Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure
10.1161/01.cir.0000159340.93220.e4 · 2005 · External reference
Effect of nesiritide in patients with acute decompensated heart failure
10.1056/nejmoa1100171 · 2011 · External reference
Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF)
10.1161/circulationaha.113.003046 · 2014 · External reference
Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial
10.1001/jama.2013.282190 · 2013 · External reference
Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats
10.1161/circulationaha.110.981720 · 2011 · External reference
Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure
10.1002/ejhf.468 · 2016 · External reference
Chronic peptide therapy with B-Type Natriuretic peptide in patients with pre-clinical diastolic dysfunction (stage B heart failure)
2016 · External reference
Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide
10.1016/j.jacc.2012.07.056 · 2012 · External reference
Roles of atrial natriuretic peptide and its therapeutic use
2010 · External reference
Multicenter prospective investigation on efficacy and safety of carperitide for acute heart failure in the 'real world' of therapy
10.1253/circj.69.283 · 2005 · External reference
10.1253/circj.cj-07-0760
10.1253/circj.cj-07-0760 · 2008 · External reference
Effects of carperitide on the long-term prognosis of patients with acute decompensated chronic heart failure: the PROTECT multicenter randomized controlled study
10.1253/circj.cj-08-0130 · 2008 · External reference
Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies
10.1093/eurheartj/ehu484 · 2015 · External reference
Renal and systemic effects of urodilatin in rats with high-output heart failure
1992 · External reference
Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure
10.1152/ajpregu.00682.2004 · 2005 · External reference
Haemodynamic and renal effects of urodilatin bolus injections in patients with congestive heart failure
10.1111/j.1365-2362.1992.tb01427.x · 1992 · External reference
Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial
10.1016/j.ahj.2005.01.022 · 2005 · External reference
Renal effects of ularitide in patients with decompensated heart failure
10.1016/j.ahj.2008.02.011 · 2008 · External reference
Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload
10.1152/ajpheart.00117.2005 · 2005 · External reference
Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions
10.1093/ehjcvp/pvv040 · 2016 · External reference
A familial mutation renders atrial natriuretic peptide resistant to proteolytic degradation
10.1074/jbc.m109.010777 · 2009 · External reference
Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP
10.1016/j.jacc.2008.02.077 · 2008 · External reference
A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions
10.1016/j.jacc.2009.04.080 · 2009 · External reference
Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide
10.1073/pnas.0811851106 · 2009 · External reference
Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide
10.1172/jci116800 · 1993 · External reference
[Comparison of vasorelaxing actions of vasonatrin peptide, C-type natriuretic peptide and atrial natriuretic peptide]
1999 · External reference
[Vasorelaxing role of vasonatrin peptide in human intramammary artery in vitro]
2003 · External reference
[Comparison of inhibitory effects of three natriuretic peptides on the proliferation of pulmonary artery smooth muscle cells of rats]
2000 · External reference
Novel bifunctional natriuretic peptides as potential therapeutics
10.1074/jbc.m804538200 · 2008 · External reference
CD-NP: a novel engineered dual guanylyl cyclase activator with anti-fibrotic actions in the heart
10.1371/journal.pone.0052422 · 2012 · External reference
Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications
10.1016/j.yjmcc.2014.08.001 · 2014 · External reference
Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects
10.1177/0091270009336233 · 2009 · External reference
Delivery of short interfering ribonucleic acid-complexed magnetic nanoparticles in an oscillating field occurs via caveolae-mediated endocytosis
10.1371/journal.pone.0051350 · 2012 · External reference
Cenderitide-eluting film for potential cardiac patch applications
10.1371/journal.pone.0068346 · 2013 · External reference
Alternative splicing as a biomarker and potential target for drug discovery
10.1038/aps.2015.43 · 2015 · External reference
A randomized trial of intensive versus standard blood-pressure control
10.1056/nejmoa1511939 · 2015 · External reference
Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease
10.1161/hypertensionaha.114.03936 · 2015 · External reference
Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation
10.1016/j.yjmcc.2011.03.013 · 2011 · External reference
A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension
10.1161/hypertensionaha.110.159210 · 2010 · External reference
M-atrial natriuretic peptide and nitroglycerin in a canine model of experimental acute hypertensive heart failure: differential actions of 2 cGMP activating therapeutics
10.1161/jaha.113.000206 · 2014 · External reference
Aldosterone levels, atrial natriuretic peptide and resistant hypertension in the general community
10.1016/j.jash.2016.03.095 · 2016 · External reference
A first-in-human trial of a novel designer natriuretic peptide ZD100 in human hypertension
10.1016/j.jash.2016.03.051 · 2016 · External reference
